Cellular immune dysregulation in the pathogenesis of immune thrombocytopenia.
Journal
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis
ISSN: 1473-5733
Titre abrégé: Blood Coagul Fibrinolysis
Pays: England
ID NLM: 9102551
Informations de publication
Date de publication:
Mar 2020
Mar 2020
Historique:
pubmed:
25
1
2020
medline:
21
7
2020
entrez:
25
1
2020
Statut:
ppublish
Résumé
: Immune thrombocytopenia (ITP) is an acquired autoimmune hemorrhagic disease characterized by immune-mediated increased platelet destruction and decreased platelet production, resulting from immune intolerance to autoantigen. The pathogenesis of ITP remains unclear, although dysfunction of T and B lymphocytes has been shown to be involved in the pathogenesis of ITP. More recently, it is found that dendritic cells, natural killer, and myeloid-derived suppressor cells also play an important role in ITP. Elucidating its pathogenesis is expected to provide novel channels for the targeted therapy of ITP. This article will review the role of different immune cells in ITP.
Identifiants
pubmed: 31977328
doi: 10.1097/MBC.0000000000000891
pii: 00001721-202003000-00001
doi:
Substances chimiques
Autoantigens
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
113-120Références
Gernsheimer T. Chronic idiopathic thrombocytopenic purpura: mechanisms of pathogenesis. Oncologist 2009; 14:12–21.
Grodzielski M, Goette NP, Glembotsky AC, Constanza Baroni Pietto M, Méndez-Huergo SP, Pierdominici MS, et al. Multiple concomitant mechanisms contribute to low platelet count in patients with immune thrombocytopenia. Sci Rep 2019; 9:2208.
Audia S, Mahévas M, Samson M, Godeau B, Bonnotte B. Pathogenesis of immune thrombocytopenia. Autoimmun Rev 2017; 16:620–632.
McKenzie CG, Guo L, Freedman J, Semple JW. Cellular immune dysfunction in immune thrombocytopenia (ITP). Br J Haematol 2013; 163:10–23.
Hou Y, Feng Q, Xu M, Li GS, Liu XN, Sheng Z, et al. High-dose dexamethasone corrects impaired myeloid-derived suppressor cell function via Ets1 in immune thrombocytopenia. Blood 2016; 127:1587–1597.
Ebbo M, Audonnet S, Grados A, Benarous L, Mahevas M, Godeau B, et al. NK cell compartment in the peripheral blood and spleen in adult patients with primary immune thrombocytopenia. Clin Immunol 2017; 177:18–28.
Raphael I, Nalawade S, Eagar TN, Forsthuber TG. T cell subsets and their signature cytokines in autoimmune and inflammatory diseases. Cytokine 2015; 74:5–17.
Li J, Wang Z, Hu S, Zhao X, Cao L. Correction of abnormal T cell subsets by high-dose dexamethasone in patients with chronic idiopathic thrombocytopenic purpura. Immunol Lett 2013; 154:42–48.
Talaat RM, Elmaghraby AM, Barakat SS, El-Shahat M. Alterations in immune cell subsets and their cytokine secretion profile in childhood idiopathic thrombocytopenic purpura (ITP). Clin Exp Immunol 2014; 176:291–300.
Zhou SF, Ma J, Qu HT, Liu ZT, He WD, Wang JD, et al. Characterization of Th1- and Th2-associated chemokine receptor expression in spleens of patients with immune thrombocytopenia. J Clin Immunol 2013; 33:938–946.
Wu X, Tian J, Wang S. Insight into non-pathogenic Th17 cells in autoimmune diseases. Front Immunol 2018; 9:1112.
Rocha AM, Souza C, Rocha GA, de Melo FF, Clementino NC, Marino MC, et al. The levels of IL-17A and of the cytokines involved in Th17 cell commitment are increased in patients with chronic immune thrombocytopenia. Haematologica 2011; 96:1560–1564.
Zhou L, Xu F, Chang C, Tao Y, Song L, Li X. Interleukin-17-producing CD4+ T lymphocytes are increased in patients with primary immune thrombocytopenia. Blood Coagul Fibrinolysis 2016; 27:301–307.
Zhang Y, Ma T, Zhou X, Chen J, Li J. Circulating level of Th17 cells is associated with sensitivity to glucocorticoids in patients with immune thrombocytopenia. Int J Hematol 2018; 107:442–450.
Lyu M, Li Y, Hao Y, Lyu C, Huang Y, Sun B, et al. CCR6 defines a subset of activated memory T cells of Th17 potential in immune thrombocytopenia. Clin Exper Immunol 2019; 195:345–357.
Duhen T, Geiger R, Jarrossay D, Lanzavecchia A, Sallusto F. Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells. Nat Immunol 2009; 10:857–863.
Azizi G, Yazdani R, Hamid KM, Razavi A, Mirshafiey A. IL-22 produced by T helper cell 22 as a new player in the pathogenesis of immune thrombocytopenia. Endocr Metab Immune Disord Drug Targets 2015; 15:242–250.
Zhan FX, Li J, Fang M, Ding J, Wang Q. Importance of Th22 cell disequilibrium in immune thrombocytopenic purpura. Med Sci Monit 2018; 24:8767–8772.
Cao J, Chen C, Li L, Ling-yu Z, Zhen-yu L, Zhi-ling Y, et al. Effects of high-dose dexamethasone on regulating interleukin-22 production and correcting Th1 and Th22 polarization in immune thrombocytopenia. J Clin Immunol 2012; 32:523–529.
Sakaguchi S, Miyara M, Costantino CM, Hafler DA. FOXP3+ regulatory T cells in the human immune system. Nat Rev Immunol 2010; 10:490–500.
Schmetterer KG, Neunkirchner A, Pickl WF. Naturally occurring regulatory T cells: markers, mechanisms, and manipulation. FASEB J 2012; 26:2253–2276.
Yang ZG, Wen RT, Zhang YM, Wu GC, Chen WJ, Wang YF, et al. Thalidomide induce response in patients with corticosteroid-resistant or relapsed ITP by upregulating Neuropilin-1 expression. Int Immunopharmacol 2019; 72:437–444.
Nishimoto T, Kuwana M. CD4+CD25+Foxp3+ regulatory T cells in the pathophysiology of immune thrombocytopenia. Semin Hematol 2013; 50:S43–S49.
Aboul-Fotoh Lel M, Abdel Raheem MM, El-Deen MA, Osman AM. Role of CD4+CD25+ T cells in children with idiopathic thrombocytopenic purpura. J Pediatr Hematol Oncol 2011; 33:81–85.
Lu Y, Cheng L, Li F, Ji L, Shao X, Wu B, et al. The abnormal function of CD39+ regulatory T cells could be corrected by high-dose dexamethasone in patients with primary immune thrombocytopenia. Ann Hematol 2019; 98:1845–1854.
Zhao HY, Ma YH, Li DQ, Sun T, Li LZ, Li P, et al. Low-dose chidamide restores immune tolerance in ITP in mice and humans. Blood 2019; 133:730–742.
Olsson B, Andersson PO, Jernas M, Jacobsson S, Carlsson B, Carlsson LM, et al. T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nat Med 2003; 9:1123–1124.
Li S, Wang L, Zhao C, Li L, Peng J, Hou M. CD8+ T cells suppress autologous megakaryocyte apoptosis in idiopathic thrombocytopenic purpura. Br J Haematol 2007; 139:605–611.
Qiu J, Liu X, Li X, Zhang X, Han P, Zhou H, et al. CD8(+) T cells induce platelet clearance in the liver via platelet desialylation in immune thrombocytopenia. Sci Rep 2016; 6:27445.
Guo L, Kapur R, Aslam R, Speck ER, Zufferey A, Zhao Y, et al. CD20+ B-cell depletion therapy suppresses murine CD8+ T-cell-mediated immune thrombocytopenia. Blood 2016; 127:735–738.
Audia S, Samson M, Mahevas M, Ferrand C, Trad M, Ciudad M, et al. Preferential splenic CD8(+) T-cell activation in rituximab-nonresponder patients with immune thrombocytopenia. Blood 2013; 122:2477–2486.
Zhou H, Qiu JH, Wang T, Yu YY, Liu XN, Li X, et al. Interleukin 27 inhibits cytotoxic T-lymphocyte-mediated platelet destruction in primary immune thrombocytopenia. Blood 2014; 124:3316–3319.
Yu Y, Ma X, Gong R, Zhu J, Wei L, Yao J. Recent advances in CD8(+) regulatory T cell research. Oncol Lett 2018; 15:8187–8194.
Ma L, Simpson E, Li J, Xuan M, Xu M, Baker L, et al. CD8+ T cells are predominantly protective and required for effective steroid therapy in murine models of immune thrombocytopenia. Blood 2015; 126:247–256.
Li H, Hao Y, Zhang D, Liu W, Li Y, Lyu M, et al. Numerical and functional defects in CD8(+) CD28(-) T-suppressor lymphocytes from patients with primary immune thrombocytopenia. Br J Haematol 2017; 178:292–301.
Fazilleau N, Mark L, McHeyzer-Williams LJ, McHeyzer-Williams MG. Follicular helper T cells: lineage and location. Immunity 2009; 30:324–335.
Ueno H. T follicular helper cells in human autoimmunity. Curr Opin Immunol 2016; 43:24–31.
Audia S, Rossato M, Santegoets K, Spijkers S, Wichers C, Bekker C, et al. Splenic TFH expansion participates in B-cell differentiation and antiplatelet-antibody production during immune thrombocytopenia. Blood 2014; 124:2858–2866.
Audia S, Rossato M, Trad M, Samson M, Santegoets K, Gautheron A, et al. B cell depleting therapy regulates splenic and circulating T follicular helper cells in immune thrombocytopenia. J Autoimmun 2017; 77:89–95.
Xie J, Cui D, Liu Y, Jin J, Tong H, Wang L, et al. Changes in follicular helper T cells in idiopathic thrombocytopenic purpura patients. Int J Biol Sci 2015; 11:220–229.
Dai L, He L, Wang Z, Bai X, He Y, Cao L, et al. Altered circulating T follicular helper cells in patients with chronic immune thrombocytopenia. Experimental and therapeutic medicine 2018; 16:2471–2477.
Reboursiere E, Fouques H, Maigne G, Johnson H, Chantepie S, Gac AC, et al. Rituximab salvage therapy in adults with immune thrombocytopenia: retrospective study on efficacy and safety profiles. Int J Hematol 2016; 104:85–91.
Liu Z, Davidson A. BAFF and selection of autoreactive B cells. Trends Immunol 2011; 32:388–394.
Kamhieh-Milz J, Ghosoun N, Sterzer V, Salama A. Effect of glucocorticoid treatment on BAFF and APRIL expression in patients with immune thrombocytopenia (ITP). Clin Immunol 2018; 188:74–80.
Zhu XJ, Shi Y, Peng J, Guo CS, Shan NN, Qin P, et al. The effects of BAFF and BAFF-R-Fc fusion protein in immune thrombocytopenia. Blood 2009; 114:5362–5367.
Douagi I, Gujer C, Sundling C, Adams WC, Smed-Sorensen A, Seder RA, et al. Human B cell responses to TLR ligands are differentially modulated by myeloid and plasmacytoid dendritic cells. J Immunol 2009; 182:1991–2001.
Zhou Z, Li X, Li J, Su C, Zhuang L, Luo S, et al. Direct B-cell stimulation by peripheral blood monocyte-derived dendritic cells in idiopathic thrombocytopenic purpura patients. J Clin Immunol 2010; 30:814–822.
Yu H, Liu Y, Han J, Yang Z, Sheng W, Dai H, et al. TLR7 regulates dendritic cell-dependent B-cell responses through BlyS in immune thrombocytopenic purpura. Eur J Haematol 2011; 86:67–74.
Yang Q, Xu S, Li X, Wang B, Wang X, Ma D, et al. Pathway of Toll-like receptor 7/B cell activating factor/B cell activating factor receptor plays a role in immune thrombocytopenia in vivo. PLoS One 2011; 6:e22708.
Mauri C, Menon M. Human regulatory B cells in health and disease: therapeutic potential. J Clin Invest 2017; 127:772–779.
Li X, Zhong H, Bao W, Boulad N, Evangelista J, Haider MA, et al. Defective regulatory B-cell compartment in patients with immune thrombocytopenia. Blood 2012; 120:3318.
Fang J, Lin L, Lin D, Zhang R, Liu X, Wang D, et al. The imbalance between regulatory memory B cells reveals possible pathogenesis involvement in pediatric immune thrombocytopenia. Hematology 2019; 24:473–479.
Aslam R, Segel GB, Burack R, Spence SA, Speck ER, Guo L, et al. Splenic lymphocyte subtypes in immune thrombocytopenia: increased presence of a subtype of B-regulatory cells. Br J Haematol 2016; 173:159–160.
Raker VK, Domogalla MP, Steinbrink K. Tolerogenic dendritic cells for regulatory T cell induction in man. Front Immunol 2015; 6:569.
Chu XX, Huang BH, Zhang XL, Chen LM, Wang Y, Yu WJ, et al. Dexamethasone inhibits immunoreactivity of dendritic cells in patients with chronic idiopathic thrombocytopenic purpura. Blood Coagul Fibrinolysis 2010; 21:564–567.
Zhang XL, Ma J, Xu M, Meng F, Qu M, Sun J, et al. Imbalance between CD205 and CD80/CD86 in dendritic cells in patients with immune thrombocytopenia. Thromb Res 2015; 135:352–361.
Webster B, Assil S, Dreux M. Cell–cell sensing of viral infection by plasmacytoid dendritic cells. J Virol 2016; 90:10050–10053.
Panda SK, Kolbeck R, Sanjuan MA. Plasmacytoid dendritic cells in autoimmunity. Curr Opin Immunol 2017; 44:20–25.
Saito A, Yokohama A, Osaki Y, Ogawa Y, Nakahashi H, Toyama K, et al. Circulating plasmacytoid dendritic cells in patients with primary and Helicobacter pylori-associated immune thrombocytopenia. Eur J Haematol 2012; 88:340–349.
Sehgal K, Guo X, Koduru S, Shah A, Lin A, Yan X, et al. Plasmacytoid dendritic cells, interferon signaling, and FcgammaR contribute to pathogenesis and therapeutic response in childhood immune thrombocytopenia. Sci Transl Med 2013; 5:193ra189.
Florez-Grau G, Zubizarreta I, Cabezon R, Villoslada P, Benitez-Ribas D. Tolerogenic dendritic cells as a promising antigen-specific therapy in the treatment of multiple sclerosis and neuromyelitis optica from preclinical to clinical trials. Front Immunol 2018; 9:1169.
Phillips BE, Garciafigueroa Y, Trucco M, Giannoukakis N. Clinical tolerogenic dendritic cells: exploring therapeutic impact on human autoimmune disease. Front Immunol 2017; 8:1279.
Kim SH, Jung HH, Lee CK. Generation, characteristics and clinical trials of ex vivo generated tolerogenic dendritic cells. Yonsei Med J 2018; 59:807–815.
Fu J, Zhang A, Ju X. Tolerogenic dendritic cells as a target for the therapy of immune thrombocytopenia. Clin Appl Thromb Hemost 2012; 18:469–475.
Siragam V, Crow AR, Brinc D, Song S, Freedman J, Lazarus AH. Intravenous immunoglobulin ameliorates ITP via activating Fc gamma receptors on dendritic cells. Nat Med 2006; 12:688–692.
Zhang A, Fu J, Ning B, Li D, Sun N, Wei W, et al. Tolerogenic dendritic cells generated with IL-10/TGFbeta1 relieve immune thrombocytopenia in mice. Thromb Res 2013; 132:63–68.
Veglia F, Perego M, Gabrilovich D. Myeloid-derived suppressor cells coming of age. Nat Immunol 2018; 19:108–119.
Boros P, Ochando J, Zeher M. Myeloid derived suppressor cells and autoimmunity. Hum Immunol 2016; 77:631–636.
Ma H, Xia CQ. Phenotypic and functional diversities of myeloid-derived suppressor cells in autoimmune diseases. Mediat Inflamm 2018; 2018:4316584.
Ozkan B, Lim H, Park SG. Immunomodulatory function of myeloid-derived suppressor cells during B cell-mediated immune responses. Int J Mol Sci 2018; 19:pii: E1468.
Zhou J, Zhou Y, Wen J, Sun X, Zhang X. Circulating myeloid-derived suppressor cells predict disease activity and treatment response in patients with immune thrombocytopenia. Braz J Med Biol Res 2017; 50:e5637.
Shao X, Wu B, Cheng L, Li F, Zhan Y, Liu C, et al. Distinct alterations of CD68(+)CD163(+) M2-like macrophages and myeloid-derived suppressor cells in newly diagnosed primary immune thrombocytopenia with or without CR after high-dose dexamethasone treatment. J Transl Med 2018; 16:48.
Zhang C, Tian Z. NK cell subsets in autoimmune diseases. J Autoimmun 2017; 83:22–30.
Wang S, Liu F, Zhao H. Eosinophil granulocyte and NK cell-mediated platelet destruction in immune thrombocytopenia. Indian J Hematol Blood Transfus 2018; 34:121–124.
He Y, Xu LL, Feng FE, Wang QM, Zhu XL, Wang CC, et al. Mesenchymal stem cell deficiency influences megakaryocytopoiesis through the TNFAIP3/NF-kappaB/SMAD pathway in patients with immune thrombocytopenia. Br J Haematol 2018; 180:395–411.
Feng Q, Xu M, Yu YY, Hou Y, Mi X, Sun YX, et al. High-dose dexamethasone or all-trans-retinoic acid restores the balance of macrophages towards M2 in immune thrombocytopenia. J Thromb Haemost 2017; 15:1845–1858.